March 17th 2023
The findings have potential clinical and public health implications and highlight the greater role of metabolic health status than obesity in IOP elevation, according to the authors.
2023: What ophthalmologists in Europe anticipate for the year ahead
December 12th 2022Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
New goniotomy device + careful post-op care limits intraoperative bleeding
December 8th 2022A new device for goniotomy has the advantage of an irrigation/aspiration system, which offers easier excision of the trabecular meshwork and better visibility. Dr Desai shares his experiences using the device as well as his tips and surgical pearls for success.
The need for precision management in glaucoma moves field forward
August 8th 2022Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and side effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.
High-tech, noninvasive imaging identifies early glaucoma
August 6th 2022Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study. This measurement could potentially be used as a first-line indicator to monitor of glaucoma progression for the patient and the physician.
Nanoemulsion formulation enhances IOP reduction, study finds
May 7th 2022In research sponsored by Skye Bioscience Inc., investigators at the University of Mississippi have demonstrated stronger and longer-lasting reduction of intraocular pressure when a proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopol 940.